Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.50 |
| ▸ | ATR | Q13535 | 7/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393120 | 0.84 | BTK (0.38) | BTKCDK1CDK4 | |
| SCHEMBL2587306 | 0.82 | ACVR1 (0.38) | BTKATR | |
| SCHEMBL1393978 | 0.81 | BTK (0.49) | BTKCDK1CDK4CCNB1CCNE1 | |
| SCHEMBL10256393 | 0.77 | BTK (0.48) | BTK | |
| SCHEMBL24374787 | 0.75 | BTK (0.53) | BTK | |
| SCHEMBL10255910 | 0.75 | MAPT (0.47) | BTKCDK4 | |
| SCHEMBL1393637 | 0.75 | BTK (0.49) | BTK | |
| SCHEMBL1393892 | 0.75 | CDK4 (0.40) | CDK1CDK4 | |
| SCHEMBL14914480 | 0.75 | BTK (0.54) | BTK | |
| SCHEMBL29741962 | 0.75 | BTK (0.54) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818724-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-107253963-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-04-14 | — | — | CN | disclosed |
| CN-110818724-A | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-8618107-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2566869-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | Gilead Connecticut, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | BTK 2/4885ATR 689/4885CDK1 19/4885 |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | BTK 2/4885ATR 689/4885CDK1 19/4885 |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | BTK 2/4885ATR 689/4885CDK1 19/4885 |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | BTK 2/4885ATR 689/4885CDK1 19/4885 |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | BTK 2/4885ATR 689/4885CDK1 19/4885 |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | BTK 2/4885ATR 991/4885CDK1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.